Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has approved APP Pharmaceuticals to market Nafcillin for injection, USP.
Subscribe to our email newsletter
APP Pharma‘s Nafcillin for injection, which is indicated for the treatment of infections caused by penicillinase-producing staphylococci, is the generic version of GlaxoSmithKline (GSK) marketed drug Nallpen and Wyeth’s Unipen.
Fresenius Kabi Pharmaceuticals’ subsidiary APP Pharma expects to market Nafcillin in 1gram and 2gram single dose vials, and a 10gram pharmacy bulk package.
APP Pharma president and CEO John Ducker said the approval of APP’s Nafcillin provides clinicians with a new supplier of this commonly used anti-infective medication.